Sign Out
Patients should be advised to avoid performing hazardous activities that require mental alertness (e.g., operating machinery, driving a motor vehicle).
Sumatriptan should be used with caution in patients with a history of seizure disorders or conditions associated with a lowered seizure threshold.
Sumatriptan should be used with caution in patients with diseases that may alter the absorption, metabolism, or excretion of the drug, such as impaired renal or hepatic function.
Sumatriptan should be avoided in patients with multiple cardiovascular risk factors (e.g., postmenopausal women; men older than 40 years of age; patients with risk factors such as hypertension, hypercholesterolemia, obesity, diabetes, smoking, or family history of coronary artery disease) who have not previously received therapy with a 5-HT1 receptor agonist. These patients should undergo cardiovascular evaluation prior to initiation of sumatriptan therapy.
Sumatriptan should only be used where there is a clear diagnosis of migraine.
Sumatriptan is not indicated for use in the management of hemiplegic, basilar or ophthalmoplegic migraine.
Before treating with sumatriptan, care should be taken to exclude potentially serious neurological conditions (e.g. CVA, TIA) if the patient presents with atypical symptoms or if they have not received an appropriate diagnosis for sumatriptan use.
